Tier 1 — highest

The Effects of Quercetin Supplementation on Blood Pressures and Endothelial Function Among Patients with Metabolic Syndrome and Related Disorders: A Systematic Review and Meta-analysis of Randomized Controlled Trials

Omid R Tamtaji, Alireza Milajerdi, Ehsan Dadgostar, Fariba Kolahdooz, Maryam Chamani, Elaheh Amirani, Hamed Mirzaei, Zatollah Asemi
Current pharmaceutical design 2019 25(12):1372-1384

Bibliography

PubMed
PMID 31092175
DOI
10.2174/1381612825666190513095352
Funding
Funding was not specified in the indexed record or the disclosure metadata available for this entry.
Competing interests
A competing-interest declaration was not available in the indexed record or the disclosure metadata used for this entry.

Study snapshot

DesignSystematic review and meta-analysis of randomized trials
ModelHuman evidence synthesis
Sample8 trials in metabolic syndrome and related disorders
InterventionQuercetin supplementation
DurationSearches through December 2018
EndpointsBlood pressure

What the study showed, in plain terms

Published in 2019, this source examined cardiovascular and metabolic health. Its evidence base was 8 trials in metabolic syndrome and related disorders. It evaluated Quercetin supplementation across Searches through December 2018.

Systolic pressure decreased modestly; diastolic pressure and measured adhesion molecules did not significantly change.

Surrogate outcomes and overlapping evidence with other reviews. This is not an additional clinical cohort or evidence of fewer cardiovascular events.

Continue with Quercetin Data Center

For topic-level interpretation, read Quercetin and Blood Pressure: How Large Is the Effect?. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • Systolic pressure decreased modestly; diastolic pressure and measured adhesion molecules did not significantly change.
  • The recorded outcome domains were Blood pressure.
  • This synthesis reuses the included study populations; it is not an additional randomized participant cohort.

What this study can and cannot tell us

  • Surrogate outcomes and overlapping evidence with other reviews. This is not an additional clinical cohort or evidence of fewer cardiovascular events.
  • Pooled estimates depend on the included trials and may share participants with companion publications or other reviews. A statistically significant surrogate outcome does not establish disease prevention.
  • Source basis: Source check: PubMed abstract and indexed metadata; full methods were not independently confirmed for this entry. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 1
The effects of Quercetin supplementation on cardiometabolic outcomes: An umbrella review of meta-analyses of randomized controlled trials
Seyyed Mostafa Arabi et al. · Phytotherapy research : PTR · 2023
Tier 1
The Effects of Quercetin Supplementation on Blood Pressure - Meta-Analysis
Joanna Popiolek-Kalisz et al. · Current problems in cardiology · 2022
Tier 1
The effects of quercetin supplementation on lipid profiles and inflammatory markers among patients with metabolic syndrome and related disorders: A systematic review and meta-analysis of randomized controlled trials
Reza Tabrizi et al. · Critical reviews in food science and nutrition · 2020

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology